Other: autologous serum and rebamipide 2% (DrugBank: Rebamipide)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03608761 (ClinicalTrials.gov) | February 6, 2017 | 9/7/2018 | Comparison Between Rebamipide 2% Versus Autologous Serum | Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study | Dry Eye Syndromes;Sjögren Syndrome | Drug: Rebamipide;Biological: autologous serum;Other: autologous serum and rebamipide 2% | Hospital Nacional Profesor Alejandro Posadas | NULL | Completed | 18 Years | N/A | Female | 21 | Phase 4 | Argentina |